Beyond Neuralink: Inside Science Corporation’s Breakthrough Vision-Restoring BCI and the Future of Neurotechnology

Main Facts

Science Corporation, a pioneering neurotechnology firm founded by former Neuralink president and co-founder Max Hodak, has reached a monumental milestone in the field of brain-computer interfaces (BCIs). Speaking on stage at TechCrunch Disrupt, Hodak announced that the company successfully implanted its vision-restoring chip, known as PRIMA, into its first human patient diagnosed with Stargardt disease. Stargardt disease is a severe, inherited eye disorder that progressively destroys central vision and is currently considered incurable.

The procedure, performed in May at the Sydney Eye Hospital in Australia, marks a significant leap forward for medical technology. The PRIMA system is designed to act as an artificial photoreceptor. During the patient’s initial rehabilitation sessions, the medical team observed rapid progress: the patient was able to visually distinguish a single letter during the first session and successfully read an entire word by the second.

While PRIMA is already commercially available in Europe for patients suffering from geographic atrophy—an advanced, blinding form of age-related macular degeneration—this latest application demonstrates the technology’s broader potential. Science Corporation is positioning its work not merely as a tool for digital communication or computer control, but as a diverse therapeutic platform capable of addressing multiple central nervous system pathologies, beginning with degenerative blindness.

Chronology

To understand Science Corporation’s current breakthrough, it is essential to trace the timeline of its development and the trajectory of its leadership:

• 2021: Following his departure from Neuralink, Max Hodak founds Science Corporation with the ambitious goal of advancing neural engineering beyond conventional paradigms, focusing on biocompatible and clinically viable BCIs.
• December 2025: Science Corporation details its unique BCI architecture, revealing a sensor designed to sit safely on top of the brain beneath the skull, contrasting sharply with devices that pierce directly into delicate brain tissue.
• April 2026: Science Corporation officially prepares to place its first advanced sensor variants into human trials, paving the way for broad clinical applications.
• May 2026: Surgeons at the Sydney Eye Hospital in Australia implant the PRIMA chip into the first-ever Stargardt disease patient as part of an ongoing clinical trial. Rehabilitation yields immediate results, with the patient reading letters and words within the first two sessions.
• July 2026: The PRIMA vision-restoring chip secures official European regulatory approval, marking a major commercial milestone for the company’s ophthalmic portfolio.
• October 2026: Max Hodak takes the stage at TechCrunch Disrupt to publicly announce the successful Stargardt patient implantation, outlining a sweeping 5-year roadmap for high-acuity artificial vision and broader neurological treatments.

Supporting Data and Technical Architecture

The technical mechanics behind the PRIMA implant bridge the gap between biological optics and digital signal processing. The device is remarkably compact, measuring a mere two millimeters by two millimeters. It is surgically placed beneath the retina at the back of the eye, directly targeting the region where natural photoreceptors have degenerated.

How the PRIMA System Operates:

1. Implantation: Patients undergo a streamlined, roughly one-hour surgical procedure to place the microchip under the retina, where outer photoreceptors have died while leaving the inner retinal pathways intact.
2. External Capture: Patients wear specialized glasses equipped with an integrated high-definition micro-camera.
3. Data Transmission: The glasses capture the visual environment and project it as infrared light beams directly onto the sub-retinal chip.
4. Neural Translation: The chip converts these light patterns into electrical impulses, stimulating the surviving inner retinal cells. These signals travel down the optic nerve, tricking the brain into perceiving visual data.

"The retina is part of the central nervous system," Hodak explained during his TechCrunch Disrupt presentation. "We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs… Vision is electrical potential, like electrical activity down the optic nerve. That’s all vision is to the brain, and so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it."

Current Limitations and Future Engineering Goals

Despite the extraordinary success of the initial implantation, the current iteration of the PRIMA chip comes with notable structural trade-offs. Because of its microscopic size, Hodak compares the patient’s perspective to "looking through a straw."

• Field of View: The current image output is a localized patch in the patient’s central vision. It is strictly monochromatic (black-and-white), though exceptionally sharp and high-contrast.
• Next-Generation Roadmap: Science Corporation is actively developing a next-generation device scheduled for human testing within the next year.
• Acuity Goals: Over the next five years, the engineering team aims to solve the complex challenges of managing retinal curvature on larger chips and shrinking electrode sizes to approach native, natural-level visual acuity and expand the field of view.

Official Responses and Strategic Vision

Science Corporation’s overarching philosophy diverges from the hyper-publicized consumer tech focus seen elsewhere in the neurotech industry. By prioritizing blinding retinal diseases first, the company is ensuring rigorous clinical validation and establishing a sustainable commercial foundation.

Max Hodak emphasized that the company’s long-term roadmap extends far beyond ophthalmology. While Neuralink’s flagship designs involve invasive thread insertion directly into cerebral cortex tissue, Science Corporation’s cranial sensors are engineered to rest smoothly on top of the brain. This design philosophy minimizes tissue trauma while opening doors to treat diverse neurological conditions.

"In the near term, we’re going to be applying our first clinical indication—which hasn’t been announced publicly—to a neurodegenerative disease that everybody’s heard of," Hodak revealed.

Furthermore, the company is researching applications for stroke recovery. Hodak noted that by establishing deep-brain neural connections across disparate areas, medical technology could effectively bridge regions of dead tissue caused by strokes, potentially introducing entirely new functional cortical areas—a feat unattainable with conventional electrode arrays.

Looking toward the horizon, Hodak shared a profound philosophical outlook: "I’d say longer term, the long-term mission of the company is to understand how the brain creates the mind and to learn to build engineered brains."

Implications for Medicine and Society

The successful deployment of the PRIMA chip in a Stargardt disease patient carries profound implications for the future of medicine, aging, and human enhancement.

1. Eradicating Incurable Blindness

Stargardt disease and geographic atrophy have historically represented irreversible pathways to legal blindness, leaving over 150,000 individuals worldwide with progressive central vision loss and limited therapeutic options. Devices like PRIMA convert "incurable" diagnoses into manageable conditions, offering patients functional independence—such as the ability to read text, recognize faces, and navigate environments unaided.

2. Redefining Brain-Computer Interfaces as Healthcare Essentials

While much cultural fascination surrounds BCIs as luxury accessories for gaming, productivity, or digital telepathy, Science Corporation is anchoring the industry firmly in preventative gerontology and regenerative medicine. Hodak noted that while the company is not currently designing devices for healthy young adults, demographic realities suggest that assistive neural technologies will become commonplace medical interventions for aging populations by the age of 60 or 70.

"We want to figure out how do we extend not just lifespan, but health span," Hodak stated.

3. Broadening the Neurological Toolkit

By validating that the central nervous system can successfully interface with external digital processors via non-destructive, surface-level cranial and retinal implants, Science Corporation is accelerating the convergence of neurology, ophthalmology, and advanced microelectronics. As electrode miniaturization improves and biocompatible materials advance, the boundary between biological tissue and engineered restoration will continue to dissolve, ushering in a new era of medical miracles for patients once thought beyond the reach of modern science.